Canine Cytochrome P-450 Pharmacogenetics - 27/07/13
Résumé |
The cytochrome P-450 (CYP) drug metabolizing enzymes are essential for the efficient elimination of many clinically used drugs. These enzymes typically display high interindividual variability in expression and function resulting from enzyme induction, inhibition, and genetic polymorphism thereby predisposing patients to adverse drug reactions or therapeutic failure. There are also substantial species differences in CYP substrate specificity and expression that complicate direct extrapolation of information from humans to veterinary species. This article reviews the available published data regarding the presence and impact of genetic polymorphisms on CYP-dependent drug metabolism in dogs in the context of known human-dog CYP differences.
Le texte complet de cet article est disponible en PDF.Keywords : Dog, Canine, Genetic polymorphism, Cytochrome P-450, Pharmacokinetics
Plan
Disclosures: This work was supported by funds provided by the William R. Jones Endowed Chair in Veterinary Medicine at Washington State University. There are no conflicts of interest to report. |
Vol 43 - N° 5
P. 1027-1038 - septembre 2013 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?